Genevoyager (Wuhan) Co., Ltd. is dedicated to the development of large-scale viral vector preparation technology, offering services for gene therapy research and drug development and production. Our goal is to establish a globally leading platform for gene therapy drug research and production, promoting collaborations to make gene therapy drugs more effective, safer, and cost-efficient for the benefit of patients.
Genevoyager gene therapy CRO/CDMO service platform currently has over 300 employees, including approximately 200 research and development professionals. We operate within a total area of over 10,000 m2, consisting of a 4,000 m2 laboratory and a 6,400 m2 cGMP workshop, which has undergone successful commissioning and commenced production in October.
Our subsidiary, BrainVTA (Wuhan) Co., Ltd., has been providing viral vector CRO services for nearly 10 years.
TECHNOLOGY PLATFORM
Partnership
Genevoyager has built a cooperation platform with many research units, medical units and famous enterprises.
US: 3675 Market Street, Suite 200, Philadelphia, PA19104 Tel: +1 (215) 205-6963 | +086 027-65023363
E-mail: hui.wang@genevoyager.com
China: No128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China Tel: 17720522078
E-mail: marketing@genevoyager.com